Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb 29:5:F1000 Faculty Rev-238.
doi: 10.12688/f1000research.7210.1. eCollection 2016.

Tumour Cell Heterogeneity

Laura Gay  1 , Ann-Marie Baker  1 , Trevor A Graham  1
Affiliations
Review

Tumour Cell Heterogeneity

Laura Gay et al. F1000Res. .

Abstract

The population of cells that make up a cancer are manifestly heterogeneous at the genetic, epigenetic, and phenotypic levels. In this mini-review, we summarise the extent of intra-tumour heterogeneity (ITH) across human malignancies, review the mechanisms that are responsible for generating and maintaining ITH, and discuss the ramifications and opportunities that ITH presents for cancer prognostication and treatment.

Keywords: Cancer evolution; evolutionary biomarkers; intra-tumour heterogeneity; personalised medicine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare that they have nothing to disclose. No writing assistance was used.

No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. Intra-tumour heterogeneity and prognostication.
( A) Intra-tumour heterogeneity means a targeted biopsy may miss a lesion with a poor prognostic signature (“red” phenotype) within the tumour (majority of tumour has a “blue” phenotype that is associated with a good prognosis). ( B) Differences between tumours (inter-tumour heterogeneity) mean that a single prognostic biomarker may be unsuitable for use in some tumours that have evolved along a different carcinogenic pathway; this yellow tumour does contain either the previously identified good (blue) or bad (red) phenotypes. ( C) Epistasis between genes (or other intra- or inter-cellular interactions) can alter the prognostic value of any individual feature; here, the presence of the “green” mutation may alter the bad prognosis of the “red” mutation assayed in ( A). ( D) Inter-cancer heterogeneity means that a feature-based prognostic marker developed for one cancer type is unlikely to work in another cancer type.
Figure 2.
Figure 2.. Intra-tumour diversity as a universal prognostic marker.
A homogeneous tumour ( A) will be eradicated in response to a selective pressure such as chemotherapy, whereas a heterogeneous tumour ( B) is more likely to contain a pre-existing resistant clone that survives the selective pressure and seeds the repopulation of the tumour.
See this image and copyright information in PMC

References

    1. Hirsch FR, Ottesen G, Pødenphant J, et al. : Tumor heterogeneity in lung cancer based on light microscopic features. A retrospective study of a consecutive series of 200 patients, treated surgically. Virchows Arch A Pathol Anat Histopathol. 1983;402(2):147–53. 10.1007/BF00695056 - DOI - PubMed
    1. Fitzgerald PJ: Homogeneity and heterogeneity in pancreas cancer: presence of predominant and minor morphological types and implications. Int J Pancreatol. 1986;1(2):91–4. - PubMed
    1. Marusyk A, Almendro V, Polyak K: Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12(5):323–34. 10.1038/nrc3261 - DOI - PubMed
    1. Fisher R, Pusztai L, Swanton C: Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108(3):479–85. 10.1038/bjc.2012.581 - DOI - PMC - PubMed
    1. Barber LJ, Davies MN, Gerlinger M: Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Curr Opin Genet Dev. 2015;30:1–6. 10.1016/j.gde.2014.12.001 - DOI - PMC - PubMed

LinkOut - more resources